# Indiana Alzheimer's Disease Research Center

> **NIH NIH P30** · INDIANA UNIVERSITY INDIANAPOLIS · 2022 · $3,047,320

## Abstract

Project Summary – IADRC Overall
The Indiana Alzheimer’s Disease Research Center (IADRC) was established in 1991 to bring investigators and
institutional resources at the Indiana University School of Medicine (IUSM) together to address the fundamental
causes and treatment of Alzheimer’s disease (AD) and related dementias (ADRD). Despite many important
gains, the need for targeted research is greater than ever, with an estimated 5.8 million people in the U.S.
suffering from AD/ADRD. Unfortunately, we do not yet know how to prevent AD or have an approved disease
modifying intervention. Both are critical to stem the growth in dementia prevalence. The overarching goal of the
IADRC going forward is to support the goal of the NAPA to prevent and effectively treat AD by 2025, through
innovative research on etiology, early detection, and therapeutics. Biomarker studies indicate that processes
leading to AD begin at least 20 years prior to dementia, suggesting that successful interventions must be
implemented early. This presents a potential opportunity for early intervention, but the field is challenged by
critical barriers decreasing the prospects of timely success. The IADRC has identified the barriers as: a) The
current understanding of etiology and pathophysiology is fragmented and incomplete; b) Sensitive, specific, and
cost-effective methods for early detection are not available; c) Therapeutic development is hampered by the
heterogeneity and complexity of ADRD; d) Shortage of data and translational scientists; and, e) Inadequate
diversity at all levels. The IADRC specific aims entail innovation to overcome these barriers and accelerate
research toward prevention and effective treatment: 1) Support, enhance, and expand innovative research on
ADRD targeting causes, diagnosis, treatment, and prevention; 2) Provide critical research resources and
infrastructure to support existing studies and enable new innovative research, utilizing a well-characterized
longitudinal clinical cohort, with prioritization of diverse populations including underrepresented groups (URG)
and those in preclinical and early symptomatic phases, including subjective cognitive decline and mild cognitive
impairment, which will help to advance the identification of easily accessible biomarkers for early detection; 3)
Identify and prioritize novel therapeutic targets from high-throughput approaches with rapid translation to proof-
of-concept studies using genetic and other enrichment strategies for better biological targeting and reduction of
phenotypic and biological heterogeneity for more efficient and cost-effective clinical trials; 4) Increase the number
of investigators with deep expertise in advanced data sciences to bridge cellular/molecular processes of
neurodegeneration and clinical phenotypes, as well as clinical and translational researchers who can move
therapeutic approaches from model systems to clinical trials; 5) Provide educational and training opportunities
related...

## Key facts

- **NIH application ID:** 10475170
- **Project number:** 5P30AG072976-02
- **Recipient organization:** INDIANA UNIVERSITY INDIANAPOLIS
- **Principal Investigator:** ANDREW J SAYKIN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $3,047,320
- **Award type:** 5
- **Project period:** 2021-09-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10475170

## Citation

> US National Institutes of Health, RePORTER application 10475170, Indiana Alzheimer's Disease Research Center (5P30AG072976-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10475170. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*